Royalty Pharma plc Profit Margin

As of the most recent data (June 2026), RPRX shows a profit margin of 32.14%. That compares with 44.26% in the prior-year period — down 27.4% year over year. That is above the Healthcare sector average of 13.76%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RPRX's profit margin is now 32.14% (was 44.26%) — a 27.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Royalty Pharma plc is outperforming or lagging.

The Healthcare sector average profit margin is about 13.76%. Royalty Pharma plc is at 32.14%, which is higher that average. That is roughly 133.5% above the sector mean. Use the comparison chart on this page to see how RPRX stacks up against individual peers as well.

That compares with 44.26% in the prior-year period — down 27.4% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Royalty Pharma plc with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Royalty Pharma plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 32.14%) with ownership activity and broader fundamentals.